Daclizumab induction in solid organ transplantation

Expert Opinion on Biological Therapy

Volumn 4, Issue 5, 2004, Pages 729-740

  Wiland, Anne M ^a   Philosophe, Benjamin ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Daclizumab; Heart; Induction therapy; Kidney; Liver; Lung; Pancreas; Transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

AFRICAN AMERICAN; ANTIBODY PRODUCTION; CAUCASIAN; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TOLERABILITY; ECONOMIC EVALUATION; GRAFT FAILURE; GRAFT REJECTION; HEART TRANSPLANTATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HISPANIC; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LONG TERM CARE; LUNG TRANSPLANTATION; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; OUTCOMES RESEARCH; PANCREAS TRANSPLANTATION; POSTOPERATIVE PERIOD; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 2442665205     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.5.729     Document Type: Review

References (52)

1. HENRY ML, RAJAB A: The use of basiliximab in solid organ transplantation. Expert Opin. Pharmacother. (2002) 3(11):1657-1663.
2. FERGUSON R: Acute rejection episodes-best predictor of long term primary cadaveric renal transplant survival. Clin. Transplant. (1994) 8:328-331.
3. QUEEN C, SCHNEIDER WP, SELICK HE et al.: A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA (1989) 86:10029-10033.
4. HAKIMI J, MOULD D, WALDMANN TA et al.: Development of Zenapax: a humanized anti-Tac antibody. In: Antibody Therapeutics. Harris WJ, Adair JR (Eds), CRC Press, New York, USA (1997):277-233.
5. HAKIMI J, CHIZZONITE R, LUKE DR et al.: Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J. Immunol. (1991) 147:1352-1359.
6. VINCENTI F, LANTZ M, BIRNBAUM J et al.: A Phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplant recipients. Transplantation (1997) 63:33-38.
7. VINCENTI F, PACE D, BIRNBAUM J, LANTZ M: Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am. J. Transplant. (2003) 3:50-52.
8. KOCH M, NIEMEYER G, PATEL I et al.: Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation (2002) 73:1640-1646.
9. VINCENTI F, KIRKMAN R, LIGHT S et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N. Engl. J. Med. (1998) 338:161-165.
10. NASHAN B, LIGHT S, HARDIE IR et al.: Reduction of acute renal allografts rejection by daclizumab. Transplantation (1999) 67:110-115.
11. EKBERG H, BÄCKMAN L, TUFVESON G et al.: Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Tanspl. Int. (2000) 13:151-159.
12. BUMGARDNER GL, HARDIE I, JOHNSON RWG et al.: Results of 3-year Phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation (2001) 72:839-845.
13. CIANCIO G, BURKE GW, SUZART K et al.: Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation (2002) 73:1100-1106.
14. CIANCIO G, BURKE GW, GAYNOR JJ et al.: A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (Neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation (2004) 77:244-251.
15. CIANCIO G, BURKE GW, GAYNOR JJ et al.: A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/ mycophenolate mofetil versus cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation (2004) 77:252-258.
16. ADU D, COCKWELL P, IVES NJ et al.: Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomized trials. Br. Med. J. (2003) 326:1-5.
17. WEBSTER AC, PLAYFORD EG, HIGGINS G et al.: Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 77:166-176. A comprehensive meta-analysis evaluating the effects of IL-2Ra on outcomes such as acute rejection, graft loss and CMV infection.
18. VINCENTI F, RAMOS E, BRATTSTROM C et al.: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation (2001) 71:1282-1287.
19. AHSAN N, HOLMAN MJ, JAROWENKO MV et al.: Limited dose monoclonal IL-2 antibody induction protocol after primary kidney transplantation. Am. J. Transplant. (2002) 2:568-573.
20. VAN RIEMSDIJK IC, TERMEULEN RG, CHRISTIAANS MH et al.: Anti-CD25 prophylaxis allows steroid-free renal transplantation in tacrolimus-based immunosuppression. Scientific Program: American Transplant Congress. Washington DC (26 April - 1 May 2002) [Abstract 133].
21. CIANCIO G, BURKE GW, SUZART K et al.: Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. Transplant. Proc. (2002) 34:1944-1945.
22. SARWAL MM, VIDHUN JR, ALEXANDER SR et al.: Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation (2003) 76:1331-1339.
23. CIANCIO G, MATTIAZZI A, ROTH D et al.: The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants. Clin. Transplant. (2003) 17:428-432.
24. CIANCIO G, BURKE GW, SUZART K et al.: Effect of daclizumab, tacrolimus, and mycophenolate mofetil in racial minority first renal transplant recipients. Transplant. Proc. (2002) 34:1617-1618.
25. MEIER-KRIESCHE H-U, PALENKAR SS, FRIEDMAN GS et al.: Efficacy of daclizumab in an African-American and Hispanic renal transplant population. Transpl. Int. (2000) 13:142-145.
26. MEIER-KRIESCHE H-U, KAZA H, PALEKAR SS et al.: The effect of daclizumab in a high-risk renal transplant population. Clin. Transplant. (2000) 14:509-513.
27. EKBERG H, PERSSON NH, KÄLLEN R et al.: Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand J. Immunol. (2003) 58:670-677.
28. PHILOSOPHE B, WILAND A, MANN D et al.: Prospective randomized study comparing OKT3 and a truncated daclizumab regimen as induction for marginal kidneys at high risk for delayed graft function. Scientific Program: American Transplant Congress. Washington DC (26 April - 1 May 2002) [Abstract 402].
29. CHANG GJ, MAHANTY HD, VINCENTI F et al.: A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin. Transplant. (2000) 14:550-554.
30. BUMGARDNER GL, RAMOS E, LIN A et al.: Daclizumab (humanized anti-IL2Rα MAB) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation (2001) 72:642-647.
31. BRUCE DS, SOLLINGER HW, HUMAR A et al.: Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation (2001) 72:1637-1643.
32. STRATTA RJ, ALLOWAY RR, HODGE E, LO A: A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin. Transplant. (2002) 16:60-68.
33. STRATTA RJ, ALLOWAY RR, LO A, HODGE E: Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation (2003) 8:1260-1266.
34. ECKHOFF DE, MCGUIRE B, SELLERS M et al.: The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation (2000) 69:1867-1872.
35. FIGUERAS J, BERNARDOS A, PRIETO M et al.: Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant. Proc. (2002) 34:1511-1513.
36. WASHBURN K, SPEEG KV, ESTERL R et al.: Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation (2001) 72:1675-1679.
37. NIEMEYER G, KOCH M, LIGHT S et al.: Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients. Am. J. Transplant. (2002) 2:454-460. A study using two-dose daclizumab with a 4-year follow-up demonstrating a low incidence of acute rejection and infectious complications.
38. HEFFRON TG, SMALLWOOD GA, PILIEN T et al.: Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant. Proc. (2002) 34:1514-1515.
39. HEFFRON TG, PILLEN T, SMALLWOOD GA et al.: Pediatric liver transplantation with daclizumab induction therapy. Transplantation (2003) 75:2040-2043.
40. BENIAMINOVITZ A, ITESCU S, LIETZ K et al.: Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N. Engl. J. Med. (2000) 342:613-619.
41. MANCINI D, BENIAMINOVITZ A, EDWARDS N et al.: Effect of daclizumab induction therapy on the development of cardiac transplant vasculopathy. J. Heart Lung Transplant. (2001) 20:194.
42. CANTAROVICH M, JOYAL D, CECERE R: Early experience with low-dose daclizumab for the prevention of acute rejection in cardiac transplantation. In: Program and Abstracts of the XIX International Congress of the Transplantation Society. Miami, USA (25-30 August 2002) Abstract 2060.
43. RABAGO G, MANITO N, ALMENAR L et al.: Induction therapy with two doses of daclizumab in heart transplantation: a prospective, multi centric clinical study. Interim analysis. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria (9-12 April 2003) Abstract 53.
44. CANTAROVICH M, GIANNETTI N, CYR E et al.: Improvement of acute renal dysfunction (ARD) in heart transplant (Tx) patients (PTS) during calcineurin inhibitor (CNI) 'holiday' without rejection under anti-CD25 monoclonal antibody coverage. J. Heart Lung Transplant. (2001) 20:233.
45. CHEN CI, MALINOWSKA K, MORAN JF et al.: Treatment of acute allograft rejection with ZENAPAX in cardiac transplant recipients. Transplantation (2001) 69:S294.
46. STARLING RC, MAMELOK R, BERGH CH et al.: Efficacy and safety of daclizumab with background immunosuppressive regimen in primary cardiac recipients: 12 month analysis. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria (9-12 April 2003) Abstract.
47. GARRITY ER, VILLANUEVA J, BHORADE SM et al.: Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation (2001) 71:773-777.
48. BROCK MV, MORJA MC, FERBER L et al.: Induction therapy in lung transplantation: a prospective, controlled clinical trail comparing OKT3, anti-thymocyte globulin, and daclizumab. J. Heart Lung Transplant. (2001) 20:1282-1290.
49. BHORADE SM, VILLANUEVA J, JORDAN AM et al.: New Combination of immunosuppressive therapy decreases acute rejection in lung transplantation. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria (9-12 April 2003) Abstract 143.
50. CONTE JV, ALLAN SH, BORJA MC et al.: Is acute rejection primary in the development of obliterative bronchiolitis? A retrospective study of daclizumab and Thymoglobulin. In: Program and Abstracts of the 23rd Annual Meeting and Scientific Sessions of International Society of Heart and Lung Transplantation. Vienna, Austria (9-12 April 2003) Abstract 150.
51. CHERIKH WS, KAUFFMAN HM, MCBRIDE MA et al.: Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation (2003) 76:1289-1293. A comparison of monoclonal, polyclonal and IL-2Ra induction agents demonstrating the beneficial effects of IL-2Ra.
52. Daclizumab (Zenapax) package insert. Roche. Revised July 2003.